IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

View article:
IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share